126674-93-9

Basic information

• Product Name: 4,6-DIFLUOROINDOLINE-2,3-DIONE
• Synonyms: BUTTPARK 50\07-84;4,6-DIFLUOROINDOLINE-2,3-DIONE;4,6-DIFLUOROISATIN;4,6-Difluoro-2,3-dioxoindoline;4,6-difluoro-2,3-dihydro-1H-indole-2,3-dione;1H-Indole-2,3-dione, 4,6-difluoro-;4,6-Difluoro isatin 4,6-Difluoro indole-2,3-dione
• CAS NO: 126674-93-9
• Molecular Formula: C₈H₃F₂NO₂
• Molecular Weight: 183.11
• Product Categories: Indoles and derivatives;Boronic Acid;Heterocyclic Compounds
• Mol File: 126674-93-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.578
• Refractive Index: 1.558
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.65±0.20(Predicted)
• CAS DataBase Reference: 4,6-DIFLUOROINDOLINE-2,3-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DIFLUOROINDOLINE-2,3-DIONE(126674-93-9)
• EPA Substance Registry System: 4,6-DIFLUOROINDOLINE-2,3-DIONE(126674-93-9)

Safety Data

• Hazardous Substances Data: 126674-93-9(Hazardous Substances Data)

Usage

General Description

4,6-Difluoroindoline-2,3-dione is a chemical compound with the molecular formula C8H4F2N2O2. It is a yellow crystalline solid with a melting point of 248-250°C. 4,6-DIFLUOROINDOLINE-2,3-DIONE is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It is also used as a building block for the synthesis of various heterocyclic compounds. 4,6-Difluoroindoline-2,3-dione has potential applications in the field of medicinal chemistry and drug discovery due to its unique chemical properties. It is important to handle this compound with care and follow proper safety protocols when working with it in the laboratory.

InChI:InChI=1/C8H3F2NO2/c9-3-1-4(10)6-5(2-3)11-8(13)7(6)12/h1-2H,(H,11,12,13)

Upstream product

• 372-39-4 3,5-difluoroaniline 
• 940054-61-5 N-(3,5-difluorophenyl)-2-hydroxyiminoacetamide 
• 75-87-6 chloral 

Downstream Products

• 126674-77-9 2-amino-4,6-difluorobenzoic acid 
• 379228-58-7 5,7-difluoroquinazolin-4(3H)-one 
• 379228-57-6 methyl 2-amino-4,6-difluorobenzoate 
• 379228-33-8 5,7-bis(benzyloxy)quinazolin-4(3H)-one 
• 940054-64-8 3-(2-amino-4,6-difluorobenzylamino)-pyrrolidine-2,5-dione 
• 940054-62-6 2-amino-4,6-difluorobenzoic acid cyanomethyl ester 
• 940054-63-7 2-aminomethyl-3,5-difluorophenylamine 
• 893428-66-5 2-amino-4,6-difluoro-benzamide 
• 1467059-98-8 5-bromo-4,6-difluoro-1H-indole-3-carbaldehyde 

Relevant articles and documents

Process research and development for the kilogram manufacture of the SRC kinase inhibitor AZD0530

Process research and development of a synthetic route towards a novel SRC kinase inhibitor is described. The Medicinal Chemistry route was very long and suffered from extensive use of chlorinated solvents and chromatography. A number of steps in the Medic

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy] -5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

Src family kinases (SFKs) are nonreceptor tyrosine kinases that are reported to be critical for cancer progression. We report here a novel subseries of C-5-substituted anilinoquinazolines that display high affinity and specificity for the tyrosine kinase domain of the c-Src and Abl enzymes. These compounds exhibit high selectivity for SFKs over a panel of recombinant protein kinases, excellent pharmacokinetics, and in vivo activity following oral dosing. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) inhibits c-Src and Abl enzymes at low nanomolar concentrations and is highly selective over a range of kinases. AZD0530 displays excellent pharmacokinetic parameters in animal preclinically and in man (t1/2 = 40 h). AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily. AZD0530 is currently undergoing clinical evaluation in man.